Back

Spironolactone treatment does not cause significant hyperkalemia at patients hospitalized because of chronic or acute heart failure - a meta-analysis

29 May 2018 (08:00 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 4 - Acute Heart Failure– Treatment Pharmacotherapy HFA Premium Access Heart Failure 2018

About the speaker

Photo
Ms Juliane Wagner

University of Pecs, Pecs (Hungary)

5 More presentations in this session

Presentation thumbnail
Doctor A. Lo Forte (Messina, IT)
Abstract
Presentation thumbnail
Associate Professor W. Speidl (Vienna, AT)
Abstract
Presentation thumbnail
Doctor N. Piatrovich (Minsk, BY)
Abstract Slides
Presentation thumbnail
Doctor E. Munoz Garcia (Malaga, ES)
Abstract Slides
Presentation thumbnail

Access the full session

Session thumbnail
Poster Session 4 - Acute Heart Failure– Treatment

The Event

Event poster

Heart Failure 2018

29 May 2018 08:00 CET
You may be interested in
thumbnail
Webinar
MRAs in heart failure: what's old is new again
10 July 2023
thumbnail
Congress Presentation
Safety and efficacy of potassium binders on hyperkalemia: a novel systematic review and meta-analysis of randomized controlled trials
31 August 2025
thumbnail
Congress Presentation
Optimizing spironolactone dosing for initial treatment success in acute decompensated heart failure: a comparative efficacy study
21 March 2026
thumbnail
Congress Presentation
Risk of hyperkalemia with sacubitril/valsartan vs. RAAS inhibitor use in heart failure with reduced and preserved ejection fraction: a meta-analysis of 6 RCTs including 17,362 patients
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources